Sema4（SMFR）及其竞争对手财务调查

Sema4 (NASDAQ:SMFR – Get Rating) is one of 33 publicly-traded companies in the "Health services" industry, but how does it weigh in compared to its peers? We will compare Sema4 to similar companies based on the strength of its institutional ownership, risk, valuation, earnings, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a breakdown of recent ratings for Sema4 and its peers, as provided by MarketBeat.

Get Sema4 alerts:

Sema4 presently has a consensus price target of $2.67, indicating a potential upside of 917.81%. As a group, "Health services" companies have a potential upside of 94.17%. Given Sema4's higher possible upside, equities research analysts plainly believe Sema4 is more favorable than its peers.

Institutional and Insider Ownership

48.6% of shares of all "Health services" companies are owned by institutional investors. 21.6% of shares of all "Health services" companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Sema4 and its peers revenue, earnings per share (EPS) and valuation.

Sema4's peers have higher revenue and earnings than Sema4. Sema4 is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Sema4 has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, Sema4's peers have a beta of 1.19, indicating that their average share price is 19% more volatile than the S&P 500.

Profitability

This table compares Sema4 and its peers' net margins, return on equity and return on assets.

Summary

Sema4 peers beat Sema4 on 7 of the 12 factors compared.

Sema4 Company Profile

(Get Rating)

Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services. It also offers Sema4 Signal that enables and advances precision oncology care, from prevention to treatment to remission; and testing for carrier screening, noninvasive prenatal testing, and newborn screening, as well as hereditary cancer testing. In addition, the company provides COVID-19 testing solutions. Sema4 Holdings Corp. was incorporated in 2020 and is headquartered in Stamford, Connecticut.

Receive News & Ratings for Sema4 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sema4 and related companies with MarketBeat.com's FREE daily email newsletter.